Global Multiple Myeloma Disease Coverage Forecast and Market Analysis Report 2020

The “Multiple Myeloma Disease Coverage Forecast and Market Analysis” report has been added to ResearchAndMarkets.com’s offering. Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on […]

The “Multiple Myeloma Disease Coverage Forecast and Market Analysis” report has been added to ResearchAndMarkets.com’s offering.

Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.

Key Topics Covered:

Overview

Disease Background

  • Definition

  • Risk factors

  • Presentation

  • Symptoms

  • Diagnosis

  • Patient segmentation

  • Co-morbidities

  • Subtypes

Treatment

Epidemiology

Marketed Drugs

Pipeline Drugs

Key Regulatory Events

  • GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning

  • EMA Says Yes To GSK’s Belantamab

  • GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear

  • Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential

  • Sanofi Is Working On’ Resolving England’s Sarclisa Funding Concerns

  • New EU Approvals

  • Manufacturing Issues Ground bluebird/Bristol Ide-Cel’ CAR-T

  • Approval For New Darzalex Dosing

  • Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data

  • UK Multiple Myeloma Patients Allowed Early Access To Sanofi’s Isatuximab

  • GSK Files Its BCMA Drug In Multiple Myeloma

  • Celgene Gets Another Myeloma CAR-T Accepted Onto EMA’s PRIME

  • EU Approvals: J&J’s Darzalex Steps Ahead With New Indication

  • Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

Probability of Success

Licensing and Asset Acquisition Deals

  • Kiadis And Sanofi Sign Natural Killer Cell Therapy Pact

  • Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol

  • Harpoon Finds A Blood Cancer Partner In AbbVie

  • Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake

Clinical Trial Landscape

  • Sponsors by status

  • Sponsors by phase

  • Recent events

Drug Assessment Model

Market Dynamics

Future Trends

  • Genericization of key brands Revlimid and Velcade will substantially slow market growth

  • New BCMA-targeted therapies will contribute to growth in the multiple myeloma market over the forecast period

  • Label expansions of marketed drugs will help balance out downturn in the market

  • The growth of pipeline and newly approved drugs in the relapsed/refractory setting will be dependent on label expansions

  • to earlier lines of therapy

Consensus Forecasts

Recent Events and Analyst Opinion

  • Darzalex for Multiple Myeloma (July 31, 2020)

  • Blenrep for Multiple Myeloma (July 14, 2020)

  • Blenrep for Multiple Myeloma (July 10, 2020)

  • UCARTS1 for Multiple Myeloma (July 6, 2020)

  • Sarclisa for Multiple Myeloma (June 2, 2020)

  • Kyprolis for Multiple Myeloma (May 31, 2020)

  • Sarclisa for Multiple Myeloma (May 31, 2020)

  • CC-92480 for Multiple Myeloma (May 31, 2020)

  • Orvacabtagene Autoleucel for Multiple Myeloma (May 30, 2020)

  • JNJ-64007957 for Multiple Myeloma (May 29, 2020)

  • Xpovio for Multiple Myeloma (May 28, 2020)

  • Blenrep for Multiple Myeloma (May 27, 2020)

  • Ide-cel for Multiple Myeloma (May 13, 2020)

  • Sarclisa for Multiple Myeloma (May 12, 2020)

  • Ygalo for Multiple Myeloma (March 26, 2020)

  • Ninlaro for Multiple Myeloma (March 10, 2020)

  • Empliciti for Multiple Myeloma (March 9, 2020)

  • Xpovio for Multiple Myeloma (March 2, 2020)

  • Blenrep for Multiple Myeloma (December 16, 2019)

  • Darzalex for Multiple Myeloma (December 10, 2019)

  • C-CAR088 for Multiple Myeloma (December 7, 2019)

  • CC-93269 for Multiple Myeloma (December 7, 2019)

  • JNJ-4528 for Multiple Myeloma (December 7, 2019)

  • ide-cel for Multiple Myeloma (December 6, 2019)

  • Ninlaro for Multiple Myeloma (November 7, 2019)

  • Daratumumab-rHuPH20 (Subcutaneous) for Multiple Myeloma (September 15, 2019)

  • Multiple Drugs for Multiple Myeloma (September 13, 2019)

  • Blenrep for Multiple Myeloma (August 23, 2019)

  • CERC-007 for Multiple Myeloma (August 7, 2019)

  • Darzalex for Multiple Myeloma (July 8, 2019)

  • Xpovio for Multiple Myeloma (July 3, 2019)

  • GEN3014 for Multiple Myeloma (June 11, 2019)

  • Sarclisa for Multiple Myeloma (June 2, 2019)

  • AMG 420 for Multiple Myeloma (June 2, 2019)

  • Darzalex for Multiple Myeloma (June 2, 2019)

  • Iberdomide for Multiple Myeloma (June 2, 2019)

  • Darzalex for Multiple Myeloma (June 2, 2019)

  • Iberdomide for Multiple Myeloma (May 15, 2019)

Key Upcoming Events

Key Opinion Leader Insights

Unmet Needs

Bibliography

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/qykct3

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005515/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Next Post

China hands out $1.5m of digital currency in cashless society trial

Authorities in Shenzhen, southern China, have handed out $1.5 million of a new digital currency as part of a trial of a cashless society. Last Friday authorities gave 50,000 lottery winners the equivalent of $30 each to spend digitally by October 16, the state-run China Daily reported Monday. The digital […]